secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sana Biotechnology, Inc. (SANA)
CIK:        0001770121
Form:       8-K
Filed at:   2026-08-10T20:09:40+00:00
Accession:  0001193125-26-342371
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sana Biotech Q2 2026: Net loss narrows to $63.6M; cash $160.5M, runway into mid-2027
--------------------------------------------------------------------------------

- Q2 net loss $63.6M ($0.22/sh) vs $93.8M ($0.39) year ago; non-GAAP loss $39.7M ($0.13).
- Cash, equivalents, marketable securities $160.5M at 6/30/26; raised $93.3M from ATM and Mayo Clinic's $25M equity investment.
- SC451 IND and Phase 1/2 start expected as early as this year; SG293 first-in-human data expected as early as this year.
- UP421 14-month data published in NEJM: C-peptide present, no immunosuppression, no safety issues.
- Mayo Clinic collaboration to accelerate SC451 development; $25M equity investment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770121/000119312526342371/0001193125-26-342371-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770121/000119312526342371/sana-20260810.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-342371

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer